The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 551-558

  Straver, Marieke E ^a   Glas, Annuska M ^b   Hannemann, Juliane ^a   Wesseling, Jelle ^a   Van De Vijver, Marc J ^a   Rutgers, Emiel J Th ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Van Tinteren, Harm ^a   Van'T Veer, Laura J ^a,b   Rodenhuis, Sjoerd ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Agendia NV   (Netherlands)

Author keywords

Breast cancer; Chemosensitivity; Gene expression signature; Neoadjuvant; Predictive

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 74849111553     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0333-1     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 1:CAS:528:DC%2BD2MXkt1ansb0%3D (Pubitemid 40719106)
2. LJ van 't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen GJ Schreiber RM Kerkhoven C Roberts PS Linsley R Bernards SH Friend 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
3. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, van't Veer LJ, van de Vijver MJ (2008) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0191-2
4. M Buyse S Loi L Van't Veer G Viale M Delorenzi AM Glas MS d'Assignies J Bergh R Lidereau P Ellis A Harris J Bogaerts P Therasse A Floore M Amakrane F Piette E Rutgers C Sotiriou F Cardoso MJ Piccart 2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 1183 1192 16954471 1:CAS:528:DC%2BD28Xps1yjtLw%3D
5. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, van't Veer LJ (2008) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0130-2
6. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil GJ Schreiber JL Peterse C Roberts MJ Marton M Parrish D Atsma A Witteveen A Glas L Delahaye T van der Velde H Bartelink S Rodenhuis ET Rutgers SH Friend R Bernards 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
7. F Cardoso L Van't Veer E Rutgers S Loi S Mook MJ Piccart-Gebhart 2008 Clinical application of the 70-gene profile: the MINDACT trial J Clin Oncol 26 729 735 10.1200/JCO.2007.14.3222 18258980 (Pubitemid 351264385)
8. J Hannemann HM Oosterkamp CA Bosch A Velds LF Wessels C Loo EJ Rutgers S Rodenhuis MJ van de Vijver 2005 Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 23 3331 3342 10.1200/JCO.2005.09.077 15908647 1:CAS:528:DC%2BD2MXlsVyiu70%3D (Pubitemid 46243477)
9. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 10.1111/j.1365-2559. 1991.tb00229.x 1757079 1:STN:280:DyaK38%2FpvVSltw%3D%3D
10. C Hauser-Kronberger N Dandachi 2004 Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer J Mol Histol 35 647 653 10.1007/s10735-004-2186-6 15614619 1:CAS:528:DC%2BD2cXhtFWqsbvF (Pubitemid 41404651)
11. ML Citron DA Berry C Cirrincione C Hudis EP Winer WJ Gradishar NE Davidson S Martino R Livingston JN Ingle EA Perez J Carpenter D Hurd JF Holland BL Smith CI Sartor EH Leung J Abrams RL Schilsky HB Muss L Norton 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431 1439 10.1200/JCO.2003.09.081 12668651 1:CAS:528:DC%2BD2cXptlCks7s%3D (Pubitemid 46594092)
12. PF Lebowitz J Eng-Wong SM Swain A Berman MJ Merino CK Chow D Venzon F Zia D Danforth E Liu J Zujewski 2004 A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer Clin Cancer Res 10 6764 6769 10.1158/1078-0432.CCR-04-0976 15501952 1:CAS:528:DC%2BD2cXpslGlt7k%3D (Pubitemid 39383024)
13. JA O'Shaughnessy JL Blum 2006 Capecitabine/taxane combination therapy: evolving clinical utility in breast cancer Clin Breast Cancer 7 42 50 10.3816/CBC.2006.n.012 16764743
14. H Burris III D Yardley S Jones G Houston C Broome D Thompson FA Greco M White J Hainsworth 2004 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621 1629 10.1200/JCO.2004.08.065 15117984 1:CAS:528:DC%2BD2cXpsVWmu7k%3D (Pubitemid 41079800)
15. EA Perez VJ Suman KM Rowland JN Ingle M Salim CL Loprinzi PJ Flynn JA Mailliard CG Kardinal JE Krook AR Thrower DW Visscher RB Jenkins 2005 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 425 432 10.3816/CBC.2005.n.047 16381626 1:CAS:528:DC%2BD28XosVOlsg%3D%3D
16. CE Loo HJ Teertstra S Rodenhuis MJ van de Vijver J Hannemann SH Muller MJ Peeters KG Gilhuijs 2008 Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results AJR Am J Roentgenol 191 1331 1338 10.2214/AJR.07.3567 18941065
17. B Weigelt AM Glas LF Wessels AT Witteveen JL Peterse LJ van't Veer 2003 Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci U S A 100 15901 15905 10.1073/pnas.2634067100 14665696 1:CAS:528:DC%2BD2cXhtVCktg%3D%3D (Pubitemid 38021087)
18. AM Glas A Floore LJ Delahaye AT Witteveen RC Pover N Bakx JS Lahti-Domenici TJ Bruinsma MO Warmoes R Bernards LF Wessels LJ van't Veer 2006 Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 278 10.1186/1471-2164-7-278 17074082 1:CAS:528:DC%2BD28Xht1eisLnE (Pubitemid 44773844)
19. C Mazouni F Peintinger S Wan-Kau F Andre AM Gonzalez-Angulo WF Symmans F Meric-Bernstam V Valero GN Hortobagyi L Pusztai 2007 Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J Clin Oncol 25 2650 2655 10.1200/JCO.2006.08.2271 17602071 1:CAS:528:DC%2BD2sXosValt7s%3D (Pubitemid 47123169)
20. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn VG Vogel SR Dakhil D Tamkus KM King ER Pajon MJ Wright J Robert S Paik EP Mamounas N Wolmark 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
21. JA van der Hage CJ van de Velde JP Julien M Tubiana-Hulin C Vandervelden L Duchateau 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237 11709566
22. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 10963602 1:CAS:528: DC%2BD3cXmt1CnsLw%3D (Pubitemid 30671230)
23. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
24. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 10.1158/1078-0432.CCR-06-1109 17438091 1:CAS:528:DC%2BD2sXkt1enur0%3D (Pubitemid 46698581)
25. L Gianni M Zambetti K Clark J Baker M Cronin J Wu G Mariani J Rodriguez M Carcangiu D Watson P Valagussa R Rouzier WF Symmans JS Ross GN Hortobagyi L Pusztai S Shak 2005 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 7265 7277 10.1200/JCO.2005.02.0818 16145055 1:CAS:528:DC%2BD2MXhtF2nsL3K (Pubitemid 46202341)
26. S Paik G Tang S Shak C Kim J Baker W Kim M Cronin FL Baehner D Watson J Bryant JP Costantino CE Geyer Jr DL Wickerham N Wolmark 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726 3734 10.1200/JCO.2005.04.7985 16720680 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
27. JM Bueno-de-Mesquita WH van Harten VP Retel LJ van't Veer FS van Dam K Karsenberg KF Douma H van Tinteren JL Peterse J Wesseling TS Wu D Atsma EJ Rutgers G Brink AN Floore AM Glas RM Roumen FE Bellot C van Krimpen S Rodenhuis MJ van de Vijver SC Linn 2007 Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Lancet Oncol 8 1079 1087 10.1016/S1470-2045(07)70346- 7 18042430 1:CAS:528:DC%2BD2sXhsVWjurzM (Pubitemid 350182954)
28. PM Ravdin LA Siminoff GJ Davis MB Mercer J Hewlett N Gerson HL Parker 2001 Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 980 991 11181660 1:STN:280:DC%2BD3M3gsFalsg%3D%3D